west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "晚期" 119 results
  • SURGICAL CORRECTION OF OLD FRACTURE OF ZYGOMA

    The experiences from operative treatment of 72 cases of old fractures of malar bones were reported. The techniques of the corrective procedure were introduced. Besides, the importance of the treatment of old malar fractures, the peculiarities of the displacement following malar fractures and the principles of its corrective treatment, and the residual flattening of the malar bone following reduction were discussed.

    Release date:2016-09-01 11:14 Export PDF Favorites Scan
  • Application of modified designed bilobed latissimus dorsi myocutaneous flap in chest wall reconstruction of locally advanced breast cancer patients

    ObjectiveTo explore the effectiveness of the modified designed bilobed latissimus dorsi myocutaneous flap in chest wall reconstruction of locally advanced breast cancer (LABC) patients.MethodsBetween January 2016 and June 2019, 64 unilateral LABC patients were admitted. All patients were female with an average age of 41.3 years (range, 34-50 years). The disease duration ranged from 6 to 32 months (mean, 12.3 months). The diameter of primary tumor ranged from 4.8 to 14.2 cm (mean, 8.59 cm). The size of chest wall defect ranged from 16 cm×15 cm to 20 cm×20 cm after modified radical mastectomy/radical mastectomy. All defects were reconstructed with the modified designed bilobed latissimus dorsi myocutaneous flaps, including 34 cases with antegrade method and 30 cases with retrograde method. The size of skin paddle ranged from 13 cm×5 cm to 17 cm×6 cm. All the donor sites were closed directly.ResultsIn antegrade group, 2 flaps (5.8%, 2/34) showed partial necrosis; in retrograde group, 6 flaps (20%, 6/30) showed partial necrosis, 5 donor sites (16.7%, 5/30) showed partial necrosis; and all of them healed after dressing treatment. The other flaps survived successfully and incisions in donor sites healed by first intention. There was no significant difference in the incidence of partial necrosis between antegrade and retrograde groups (χ2=2.904, P=0.091). The difference in delayed healing rate of donor site between the two groups was significant (P=0.013). The patients were followed up 15-30 months, with an average of 23.1 months. The appearance and texture of the flaps were satisfactory, and only linear scar left in the donor site. No local recurrence was found in all patients. Four patients died of distant metastasis, including 2 cases of liver metastasis, 1 case of brain metastasis, and 1 case of lung metastasis. The average survival time was 22.6 months (range, 20-28 months).ConclusionThe modified designed bilobed latissimus dorsi myocutaneous flap can repair chest wall defect after LABC surgery. Antegrade design of the flap can ensure the blood supply of the flap and reduce the tension of the donor site, decrease the incidence of complications.

    Release date:2021-09-28 03:00 Export PDF Favorites Scan
  • 参麦注射液配合化疗治疗晚期乳腺癌

    【摘要】 目的 观察参麦注射液配合化疗治疗晚期乳腺癌的临床疗效。方法 2006年5月—2008年12月将60例患者随机分成治疗组(30例)与对照组(30例),两组患者化疗均用CAF方案,21~28 d为1周期,3周期为1疗程。治疗组加用参麦注射液静脉滴注,与化疗同时使用,21 d为1个疗程,每疗程间隔15 d,同时停用参麦注射液,共用3个疗程评价疗效。结果 治疗组23例患者(76.7%)坚持完成了3个疗程化疗,对照组11例(36.7%),两组差异有统计学意义(Plt;0.05)。治疗组和对照组总改善率分别为90.0%和66.7%(Plt;0.05)。两组患者CD+3、CD+4、CD+4/CD+8均有不同程度的提高,与治疗前比较差异均有统计学意义(Plt;0.05),且治疗组高于对照组(Plt;0.05)。治疗组和对照组白细胞下降发生率分别为53.3%和86.7%,恶心呕吐发生率分别为63.3%和90.0%,脱发发生率分别为43.3%和80.0%,两组差异均有统计学意义(Plt;0.05)。结论 参麦注射液配合化疗具有改善骨髓造血功能,防治白细胞减少及增进机体免疫功能作用,可减轻化疗毒副反应,提高患者生活质量。

    Release date:2016-09-08 09:37 Export PDF Favorites Scan
  • Clinical Efficacy of Ultrasound-Guided Irreversible Electroporation in Treatment of Advanced Hepatic Carcinoma

    Objective To study clinical efficacy of irreversible electroporation in the treatment of advanced hepatic carcinoma. Methods Between July 2015 and September 2015, 8 patients with advanced hepatic carcinoma (10 tumors) were treated by ultrasound-guided irreversible electroporation, using pertacuneous, laparoscope or open surgery in the Rockets Army General Hospital of PLA. Prospectively collected and summarized the clinical data. Finally, analyzed the therapeutic effect of irreversible electroporation. Results Compared with before treatment, the quality of life score significantly increased 〔(37.75±4.65) scores vs. (22.25±2.87) scores, P=0.000〕 in 3 months after treatment of irreversible electroporation, but value of serum total bilirubin (56.37 mmol/L vs. 150.40 mmol/L, P=0.046), direct bilirubin (58.69 mmol/L vs. 71.60 mmol/L, P=0.012), alanine aminotransferase 〔(52.63±12.14) U/mL vs. (87.28±27.94) U/mL, P=0.003〕, asperate aminotransferase 〔(48.45±13.75) U/mL vs. (74.40±21.09) U/mL, P=0.000〕, and alpha fetoprotein (82.10 ng/mL vs. 159.20 ng/mL, P=0.042) significantly decreased. One patient suffered from persistent upper abdominal pain after irreversible electroporation, but no serious complications, such as infection, biliary fistula, hemorrhage, and liver or kidney failure occurred in all 8 patients. Abdominal enhanced CT scanning or MRI in 3 months after irreversible electroporation showed complete ablation in 7 patients and incomplete ablation with some residual in 1 patient. Eight patients were followed up for 3-5 months 〔an average of (4.0±0.9) months〕. During follow-up period, all patients had been alive with 1 case of recurrence. Conclusion The effect of ultrasound-guided irreversible electroporation in the treatment of advanced hepatic carcinoma is remarkable, and it may deserve clinical application in consideration of its safety and efficacy.

    Release date: Export PDF Favorites Scan
  • 严重雷电击伤合并晚期妊娠护理一例

    Release date:2017-11-24 10:58 Export PDF Favorites Scan
  • 侵犯心脏大血管局部晚期肺癌的外科治疗

    摘要: 目的 总结侵犯大血管和左心房的局部晚期非小细胞肺癌的外科治疗经验。 方法 回顾性分析我科2005年2月至2009年11月期间对32例局部晚期(T4N0M0、T4N1M0、T4N2M0)非小细胞肺癌患者(男27例,女5例;年龄48~73岁,中位年龄58岁)采用原发肿瘤加部分心房或大血管切除治疗的临床资料。侵犯上腔静脉和无名静脉5例,肺动脉干4例,左心房23例。行左全肺及左心房部分切除13例,左全肺及肺动脉干部分切除4例,右全肺及左心房部分切除9例(其中2例在体外循环辅助下进行),右肺中下叶及部分左心房切除1例,右肺上叶及上腔静脉部分切除人工血管置换3例,上腔静脉修补2例。 结果 本组32例患者无手术死亡,手术完全切除16例。术后仅有3例发生心律失常。 肿瘤病理类型:鳞癌25例,腺癌5例,大细胞癌2例。术后pTNM分期:T4N0M03例,T4N1M0 11例,T4N2M0 18例。所有患者术后随访6个月~5年,中位生存时间15个月;T4N0 M0、T4N1M0患者的中位生存时间为19个月,T4N2M0患者的中位生存时间为10个月。1例患者无瘤生存5年。 结论 侵及心房大血管的局部晚期肺癌(Ⅲb期)采用扩大切除术能提高根治性手术切除率,改善患者生活质量,提高局部晚期肺癌患者的生存率。

    Release date:2016-08-30 06:02 Export PDF Favorites Scan
  • 联合PD-1抑制剂在初始不可切除胃癌转化治疗中的临床疗效观察

    目的 评价XELOX联合PD-1抑制剂在初始不可切除胃癌转化治疗中的初步疗效及安全性。方法 回顾性分析2019年2月至2021年3月期间10例就诊于北部战区总医院行XELOX联合程序性死亡受体1(programmed death receptor 1,PD-1)抑制剂治疗的晚期患者的临床及手术资料。结果 6例为PR,3例为SD,1例为CR;肿瘤退缩情况:2例0级,1例1级,3例2级,3例3级,16组淋巴结转移1例,未予切除。 转化治疗反应:5例Ⅰ级骨髓抑制,5例Ⅰ/Ⅱ级胃肠道反应,术后不全性肠梗阻1例,保守痊愈后出院。结论对于初始不可切除或难以R0根治的晚期胃癌患者,转化治疗是有效且安全的。

    Release date: Export PDF Favorites Scan
  • 应用带膜镍钛记忆合金支架治疗晚期食管癌

    目的总结应用带膜镍钛记忆合金支架治疗晚期食管癌的临床经验。方法53例晚期食管癌患者在食管X线钡餐透视下采用介入法、内镜法或术中植入法在食管内放置带膜镍钛记忆合金支架。术后进食困难程度用Neuhaus分级评估,并随访观察所有患者近期和远期疗效。结果所有患者支架均一次放置成功,无操作引起的严重并发症,术后患者吞咽困难症状明显改善,置入支架后患者吞咽困难分级较置入支架前明显降低(P〈0.01),能顺利进半流质或普通食物。狭窄食管段直径由2~4mm扩张至16~20mm。随访49例(92.5%),随访时间3~24个月。术后近期并发症主要为胸骨后异物感、疼痛、恶心和少量消化道出血,发生率为96.2%(51/5a)。26例患者(53.1%,26/49)于术后3~15个月内死亡,平均生存7.8个月,死亡原因多为肿瘤转移、全身衰竭。结论食管内放置带膜镍钛记忆合金支架治疗晚期食管癌患者的食管狭窄、食管瘘简单易行、损伤小,近期疗效明显,是一种有效的姑息性非手术治疗方法。

    Release date:2016-08-30 06:23 Export PDF Favorites Scan
  • Lenvatinib + transarterial chemoembolization + PD-1 antibody in the treatment of hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation: four case reports

    Objective To summarize the effect of lenvatinib + transarterial chemoembolization (TACE) + programmed cell death protein-1 (PD-1) antibody in the treatment of hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation. Methods In this study, we reported the clinical data of four patients with hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation who received conversion therapy with lenvatinib combined with TACE and PD-1 antibody in West China Hospital. Results Among the four patients, two patients achieved complete response and two achieved partial response; tumor markers were significantly decreased after combination treatment. However, all four patients failed to undergo hepatectomy. ConclusionsLenvatinib + TACE + PD-1 antibody is effective for hepatocellular carcinoma with main portal vein tumor thrombus and cavernous transformation. However, there are still many problems worthy of further discussion.

    Release date:2022-06-08 01:57 Export PDF Favorites Scan
  • 替吉奥治疗晚期胃癌的不良反应及其护理

    目的 总结晚期胃癌患者口服替吉奥的不良反应,探讨其护理方法。 方法 对2010年2月-11月34例口服替吉奥的晚期胃癌患者,按个体体表面积计算:口服40~60 mg/次,每日早晚饭后各服1次,服药4周,休息2周,每6周为1周期。从给药后开始观察其不良反应,及时给予护理干预,做好心理护理,用药、饮食指导等。 结果 口服替吉奥不良反应小,多为Ⅰ~Ⅱ度不良反应,主要为骨髓抑制、消化道反应、色素沉着等。Ⅲ度以上发生较少。 结论 口服替吉奥治疗晚期胃癌患者的不良反应小、疗效好,患者易接受;使治疗能顺利完成。

    Release date:2016-09-08 09:13 Export PDF Favorites Scan
12 pages Previous 1 2 3 ... 12 Next

Format

Content